Aims

Atrial electrical remodelling (AER) is a transitional period associated with the progression and long-term maintenance of atrial fibrillation (AF). We aimed to study the progression of AER in individual patients with implantable devices and AF episodes.

Methods and results

Observational multicentre study (51 centres) including 4618 patients with implantable cardioverter-defibrillator (+/-resynchronization therapy (ICD/CRT-D)) and 352 patients (2 centres) with pacemakers (median follow-up: 3.4 years). Atrial activation rate (AAR) was quantified as the frequency of the dominant peak in the signal spectrum of AF episodes with atrial bipolar electrograms. Patients with complete progression of AER, from paroxysmal AF episodes to electrically remodelled persistent AF, were used to depict patient-specific AER slopes. A total of 34 712 AF tracings from 830 patients (87 with pacemakers) were suitable for the study. Complete progression of AER was documented in 216 patients (16 with pacemakers). Patients with persistent AF after completion of AER showed ~30% faster AAR than patients with paroxysmal AF. The slope of AAR changes during AF progression revealed patient-specific patterns that correlated with the time-to-completion of AER ($R^2 = 0.85$). Pacemaker

José María Lillo-Castellano, Juan José González-Ferrer, Manuel Marina-Breysses, José Bautista Martínez-Ferrer, Luisa Pérez-Álvarez, Javier Alzueta, Juan Gabriel Martínez, Aníbal Rodríguez, Juan Carlos Rodríguez-Pérez, Ignasi Anguera, Xavier Viñolas, Arcadio García-Alberola, Jorge G. Quintanilla, José Manuel Alfonso-Almazán, Javier García, Luis Borrego, Victoria Cañadas-Godoy, Nicasio Pérez-Castellano, Julián Pérez-Villacastín, Javier Jiménez-Díaz, José Jalife, and David Filgueiras-Rama

1 Advanced Development in Arrhythmia Mechanisms and Therapy Laboratory, Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; 2 Fundación Interhospitalaria para la Investigación Cardiovascular (FIC), Madrid, Spain; 3 Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). Cardiovascular Institute, Madrid, Spain; 4 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; 5 Agencia Española de Protección de la Salud en el Deporte (AESPAD), Madrid, Spain; 6 Department of Cardiology, Hospital Universitario de Áraba, Vitoria, Spain; 7 Department of Cardiology, Hospital Hospitalario Universitario de A Coruña, La Coruña, Spain; 8 Department of Cardiology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; 9 Department of Cardiology, Hospital General Universitario de Alicante, ISABIAL-FISABIO, Alicante, Spain; 10 Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; 11 Department of Cardiology, Hospital Insular de Gran Canaria, Las Palmas, Spain; 12 Department of Cardiology, Hospital Universitario de Bellvitge, Barcelona, Spain; 13 Department of Cardiology, Hospital Santa Creu i la Caritat, Barcelona, Spain; 14 Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain; 15 Department of Cardiology, Hospital Universitario de Getafe, Madrid, Spain; 16 Department of Cardiology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; and 17 Cardiac Arrhythmia Laboratory, Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Received 5 March 2019; editorial decision 10 November 2019; accepted 12 November 2019; online publish-ahead-of-print 16 December 2019

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
patients were older than patients with ICD/CRT-Ds (78.3 vs. 67.2 year olds, respectively, $P < 0.001$) and had a shorter median time-to-completion of AER (24.9 vs. 93.5 days, respectively, $P = 0.016$). Remote transmissions in patients with ICD/CRT-D devices enabled the estimation of the time-to-completion of AER using the predicted slope of AAR changes from initiation to completion of electrical remodelling ($R^2 = 0.45$).

**Conclusion**

The AF progression shows patient-specific patterns of AER, which can be estimated using available remote-monitoring technology.

**Keywords**

Atrial fibrillation • Atrial fibrillation progression • Electrical remodeling • Implantable cardioverter-defibrillator • eHealth • Telemedicine • Mobile health

---

**What’s new?**

- Current remote-monitoring technology in implantable devices enables the identification of patient-specific slopes of atrial electrical remodelling (AER) during atrial fibrillation (AF) progression.
- Time-to-completion of AER can be estimated using the computed patient-specific slope of atrial activation rate changes and the underlying cardiac condition.
- The results represent a step forward in monitoring the progression of AER, which may further assist physicians in the stratification and personalized care of patients with AF.

---

**Introduction**

Atrial fibrillation (AF) is currently considered a growing and inevitable worldwide epidemic with important economic and social burden.\(^1\)\(^,\)\(^2\) Atrial fibrillation diagnosis is simple when using non-invasive surface electrocardiographic (ECG) recordings,\(^3\) although can also be obtained from intracardiac atrial recordings in patients with implantable devices and atrial leads.\(^4\) Characteristically, both surface and intracardiac AF tracings will show fast atrial activation rate (AAR) and irregular activity.\(^3\)\(^,\)\(^4\)

Atrial fibrillation is often a progressive cardiac arrhythmia from short-lasting episodes to long-standing persistent episodes,\(^3\) which increases the risk of hospitalization and adverse cardiovascular events.\(^5\) Atrial fibrillation itself induces progressive functional and structural changes in the atrial myocardium that facilitate long-term perpetuation of the arrhythmia.\(^6\) Concomitant genetic and cardiovascular conditions also establish an underlying substrate favouring AF initiation and perpetuation,\(^2\) although they do not provide information about individualized progression of AF remodelling as the arrhythmia persists.

Initially, AF provokes ion channel changes leading to shortening of the action potential duration and progressively faster AAR until reaching a complete electrically remodelled state.\(^6\)\(^,\)\(^7\) As AF evolves other mechanical and structural changes also progressively develop,\(^6\) which further decrease the probability of achieving a successful rhythm control strategy.\(^8\) Interestingly, in translational animal models of persistent AF, the time-course of atrial electrical remodelling (AER) has been shown to present distinct progression from animal to animal,\(^6\) whose remodelling slopes are sensitive to the effect of pharmacological treatment.\(^7\) Although monitoring AER may have diagnostic and therapeutic implications in the clinic, it has not been demonstrated that AER also follows patient-specific patterns.

We tested the hypothesis that AAR changes during AF progression show patient-specific patterns that can be estimated using clinical variables and remote-monitoring tracings from implantable devices. We aimed to study AARs and the time-course of AER progression using bipolar AF recordings obtained from two populations of patients with implantable cardioverter-defibrillator +/- re-synchronization therapy (ICD/CRT-D) and pacemaker devices. We also aimed to study the effect of the underlying clinical conditions on the AER process of AF.

---

**Methods**

**Study design**

The ICD/CRT-D data were obtained from an observational multicentre registry from 51 Spanish centres included in the UMBRELLA study (NCT01561144 at clinicaltrials.gov). This database is supported by the scientific co-operation platform, which is a cloud-based big-data tool that enables automatic and non-invasive data transmission with digitally structured storage. The database consisted of 4618 patients undergoing a Medtronic (Tolochenaz, Switzerland) ICD/CRT-D implantation from August 2011 to November 2017. A total of 2074 patients with dual-chamber ICD/CRT-D devices and remote-monitoring transmissions were considered for the study. Pacemaker data were obtained from a retrospective observational study in two Spanish centres. All patients undergoing a dual-chamber Microport (Clamart, France) pacemaker implantation from December 2009 to December 2018 were considered for the study. Atrial leads were routinely implanted in the right atrial appendage. **Figure 1** shows the study flow chart.

We obtained ethics committee approval for both ICD/CRT-D and pacemaker series in accordance with the Helsinki Declaration. All patients signed an informed consent. In patients with ICD/CRT-D devices, clinical baseline and demographic data were retrospectively collected at the time of device implantation using the official data collection sheet from the Spanish Society of Cardiology (see also Supplementary material online). In cases with device replacement during follow-up, the baseline data were selected using the data collection that was closest to the initiation of AF history. In pacemaker patients, clinical data and pharmacological history were obtained from electronic medical records during the follow-up period. In these patients, left atrial (LA) diameter was also measured using transthoracic echocardiography and a parasternal long-axis view.
Data selection and rhythm classification

The UMBRELLA scientific committee initially reviewed and classified 27461 ICD/CRT-D stored episodes registered in a digital two-channel electrogram format. Three independent investigators used a custom-made Java-based software tool (Standard Edition 8, Oracle, Redwood, CA, USA) to further review and classify 31 672 tracings obtained from remote-monitoring transmissions. Stored pacemaker tracings obtained at the time of regular device interrogations were reviewed using the same software tool. Poor signal quality tracings were excluded from the study during the review process. Then, all AF tracings with a bipolar lead configuration (tip-ring; Figure 2A), overt irregular and fast activation rates >3 Hz, and ≥3-s long recordings were included in the study. Manual selection of
AF segments were performed in tracings with documented AF termination at the end of the tracing. Signal artefacts were manually excluded if necessary.

Selected AF tracings were further classified as paroxysmal or persistent AF based on the recorded episode duration. In pacemaker patients, further confirmation of AF classification was obtained from clinical records. Atrial fibrillation episodes lasting <7 days were classified as paroxysmal AF and episodes lasting ≥7 days as persistent AF. In ICD/CRT-D patients, AF tracings without episode duration were classified using subsequent recordings in a way that two or more consecutive remote transmissions documenting AF, at least 7 days apart, were considered as persistent AF.

### Computation of atrial activation rates

Atrial signals from stored episodes (ICD/CRT-Ds and pacemakers) were obtained at 128 Hz and data from remote transmissions (ICD/CRT-Ds only) were obtained at 256 Hz. Signals were high-pass filtered with cut-off frequency of 0.5 Hz. The median duration of AF tracings per patient was 9.6 [5.03, 10.00] s in ICD/CRT-D devices and 14.6 [10.6, 19.7] s in pacemakers. Local right AAR was computed using spectral analysis and the fast Fourier transform to convert the tracing into the frequency domain as reported elsewhere. Specifically, we used the non-parametric Welch method for power spectrum estimation with a median spectral resolution per patient of 0.10 [0.06, 0.24] Hz and 0.07 [0.05, 0.09] Hz in ICD/CRT-Ds and pacemakers, respectively. Spectral information below 10 Hz was normalized to the amplitude of the highest spectral peak within this band. The dominant frequency (DF) was defined as the frequency with the highest power within this band. The DF value for each AF tracing was reviewed to detect potential harmonic peaks, and if needed, it was manually corrected to the estimated average local AAR using a custom-made Java tool. Thus, the DF peak provided a robust and rapid calculation of the reciprocal average local activation intervals (estimated average cycle length (ms) = [(1/DF) × 1000]; Figure 2B–D).

### Time-course analysis of atrial electrical remodelling

The DF-derived AARs were ordered by date to depict any changes during the follow-up period (Figure 2B). Then, patients with progression of AER from paroxysmal AF episodes (AER remodelling not present or incomplete) to persistent AF episodes with complete electrical remodelling were used to plot remodelling slopes. Pre- and post-electrical remodelling segments were manually selected using a custom-made Java tool. Because atrial activations during AF are irregular and DF values may slightly vary during consecutive tracings, we used median DF values during the pre- and post-remodelling phases to compute the difference between the two stages. Then, the slope of AER was computed automatically by fitting the DF values to a linear regression function dependent on both the median DF values and the documented date of initiation and completion of AER (Figure 2B).
Statistical analysis

All data are presented as median and inter-quartile range [25th, 75th percentiles], except where noted. Normal distribution of variables was assessed with the Shapiro–Wilk test. Statistical significance was assessed by the T-test or the Mann–Whitney–Wilcoxon test, as appropriate. The ANOVA or the Kruskal–Wallis test was used for three- to four-group comparisons according to data distribution. Categorical variables were compared using the χ² test. The log(1) function was used to transform the exponential nature of the time-to-completion of AER distribution to a normally distributed variable. Pearson’s correlation coefficient (R²) was used for correlation analysis between continuous variables and DF values during persistent AF. A P-value of <0.05 was considered statistically significant.

The large series of patients with ICD/CRT-D devices was used to study the predictive value of clinical variables to establish the time-to-completion of AER, by means of univariate analysis and a multivariate stepwise linear regression model. Then, we developed a computational method using remote-monitoring tracings to estimate patient-specific times-to-completion of AER. First, all variables statistically associated with DF values during persistent AF were included in a multivariate stepwise linear regression model to predict AAR during persistent AF after completion of AER. Then, for each patient, the time-to-completion of AER was estimated using the predicted values of AAR after completion of the AER process and the computed slope at 25% of the expected change in AAR from paroxysmal AF to complete electrical remodelling in persistent AF. The analyses were carried out using SPSS v.21 (IBM Corp., New York, NY, USA) and custom Matlab (MathWorks Inc., Natick, MA, USA) scripts for mathematical assistance.

Results

A total of 34,712 AF tracings from 830 patients (87 with pacemakers) were suitable for the study. Patients with pacemakers showed a similar follow-up period to ICD/CRT-D patients (3.4 [1.7, 5.3] and 3.4 [1.9, 4.3] years, respectively), although the former were significantly older (78.3 [73.1, 85.3] vs. 67.2 [59.3, 73.7] year old, P < 0.001, respectively) and had a predominant left ventricular ejection fraction (LVEF) >35%. Table 1 shows baseline clinical characteristics and comparisons between pacemaker and ICD/CRT-D populations. Complete progression of AER from pre-remodelling to complete remodelling in persistent AF was documented in 216 patients (16 with pacemakers). Other 543 patients in the ICD/CRT-D population and 71 patients in the pacemaker population were classified as paroxysmal AF (no progression to persistent AF during the follow-up) or persistent AF (repeated transmissions in AF during the follow-up; intermediate period between them). This increase in AAR was present in both pacemaker and ICD/CRT-D populations, although pacemaker patients showed slower AAR during paroxysmal AF episodes compared with ICD/CRT-D patients (4.12 [3.64, 4.53] Hz vs. 4.63 [4.07, 5.34] Hz, respectively, P = 0.001). These differences were not documented after completion of AER in persistent AF (Figure 3C). Moreover, in the pacemaker population, echocardiography data showed a progression in structural remodelling reflected by a significantly larger LA diameter after completion of AER compared with early electrical remodelling stages (50 [40, 56] mm vs. 38 [41, 45] mm, P = 0.006; Figure 3D).

More specific analysis of AARs in patients with an ICD or CRT-D device and complete monitoring of AER (n = 200) showed that AARs during paroxysmal AF episodes were significantly slower in CRT-D patients compared with ICD patients (4.15 [3.48, 4.80] Hz vs. 4.45 [3.81, 5.25] Hz, respectively, P = 0.005). However, these differences were not statistically significant after completion of AER in persistent AF (Supplementary material online, Figure S1). Biventricular capture in CRT-D patients was 95.4 [89.3, 99.0]%. In the pacemaker population, we also documented a trend to slower AARs under Class III antiarrhythmic drugs (Supplementary material online, Figure S2).

Prediction of atrial activation rates after completion of atrial electrical remodelling

In ICD/CRT-D patients with complete monitoring of AER, there was a statistically significant correlation between AARs during paroxysmal AF and at the completion of AER in persistent AF (R² = 0.424, P < 0.001; Figure 4A). Thus, the slower the AAR during paroxysmal AF, the slower the expected AAR after completion of AER. Moreover, AARs after completion of AER were significantly lower in patients with ICM compared with patients with DCM or other structural cardiomyopathies (6.30 [5.60, 6.70] Hz vs. 6.48 [5.96, 7.20] Hz, and vs. 6.93 [5.61, 7.45] Hz, respectively, P = 0.015 and P = 0.036, respectively; Figure 4B). Left ventricular ejection fraction <35% was also associated with lower AARs compared with LVEF >35% (6.30 [5.61, 6.79] Hz vs. 6.84 [5.72, 7.38] Hz, respectively, P = 0.013). Table 3 shows the univariate analysis of baseline clinical characteristics and any statistically significant association with AAR values during persistent AF after completion of AER. Importantly, a predictive model using the underlying cardiac condition and the AAR during early stages of AER in paroxysmal AF significantly correlated with AAR values after completion of AER in persistent AF (Table 4; R² = 0.460).

Atrial fibrillation progression shows patient-specific patterns of electrical remodelling

The log(slope) of AARs during AF progression showed patient-specific patterns that strongly correlated with the log(time-to-completion of AER), both in the ICD/CRT-D and pacemaker populations (R² = 0.852 and R² = 0.853, respectively; P < 0.001; Figure 4C and Supplementary material online, Figure S3). Using the large population of patients with ICD/CRT-D devices, univariate analysis of baseline clinical variables showed that only the presence of left bundle branch block (P = 0.036) was associated with the time-to-completion of AER (Supplementary material online, Table S1). However,
Multivariate analysis did not identify any statistically significant association of clinical variables with the time-to-completion of AER. Importantly, patient-specific time-to-completion of AER could be estimated in a subset of the ICD/CRT-D population \((n = 51)\) with remote-monitored AF tracings. Thus, the predicted value of AARs at the completion of the AER process and the computed slope at 25% of the expected change in AARs, from paroxysmal AF to complete electrical remodelling in persistent AF, correlated with the time-to-completion of AER \((R^2 = 0.458; \text{Figure 4D, E and Supplementary material online, Figure S4})\). Error quantification of the estimated log(time-to-completion of AER) showed a median value of 33.56\% [12.72, 57.06].

Further comparisons between the pacemaker population and patients with ICD/CRT-D devices showed that the time-to-completion of AER was significantly shorter in patients with pacemakers \([24.9 [14.3, 108.2] \text{ d vs. } 93.5 [36.6, 190.5] \text{ d, respectively; } P = 0.016; \text{Figure 4F})\). Despite limitations to identify the underlying causes of such differences, older ages in the pacemaker population may be involved (Table 1).

### Discussion

We studied the time-course of AER in two populations of patients with implantable devices during AF progression. Patients with paroxysmal and persistent AF showed significantly different AARs, with faster activation rates during persistent AF after completion of AER. We have identified that AAR after completion of AER could be predicted using the underlying cardiac condition and the AAR during paroxysmal AF. Moreover, we have documented patient-specific

**Table 1** Baseline clinical and demographic characteristics of implantable cardioverter-defibrillator +/- -resynchronization therapy and pacemaker populations

| Clinical characteristics | ICD/CRT-D \((n = 743)\) | Pacemaker \((n = 87)\) | P-value |
|--------------------------|--------------------------|----------------------|---------|
| Age (years), \(n\) (median [IQR]) | 67.2 [59.3, 73.7] | 78.3 [73.1, 85.3] | <0.001 |
| Male, \(n\) (%) | 609 (82.0) | 51 (68.6) | <0.001 |
| Cardiomyopathy, \(n\) (%) | | | |
| ICM | 376 (50.6) | 19 (21.8) | |
| DCM | 247 (33.2) | 1 (1.1) | |
| Other SCM: HCM, ARVC, VHD, or CHD | 97 (13.1) | 3 (3.4) | |
| Non-structural arrhythmogenic disease | 23 (3.1) | 0 (0.0) | |
| Non-cardiomyopathy | 0 (0) | 64 (73.6) | |
| LBBB, \(n\) (%) | 334 (45.6) | 12 (13.8) | <0.001 |
| LVEF <35\%, \(n\) (%) | 544 (73.4) | 4 (4.6) | <0.001 |
| Functional class, \(n\) (%) | | | <0.001 |
| NYHA I | 119 (18.2) | 34 (39.5) | |
| NYHA II | 288 (44.0) | 41 (47.7) | |
| NYHA III | 235 (35.9) | 10 (11.6) | |
| NYHA IV | 12 (1.8) | 1 (1.2) | |
| Clinical history, \(n\) (%) | | | |
| Hypertension | 434 (59.9) | 77 (88.5) | <0.001 |
| Diabetes mellitus | 227 (31.2) | 25 (28.7) | 0.641 |
| Hyperlipidaemia | 388 (54.6) | 50 (57.5) | 0.608 |
| Current smoking | 206 (30.2) | 5 (5.7) | <0.001 |
| Chronic renal failure | 143 (20.0) | 12 (13.8) | 0.168 |
| Previous stroke or TIA | 50 (7.5) | 6 (6.9) | 0.852 |
| Medications during the AF period, \(n\) (%) | | | |
| \(\beta\)-blocker | – | 40 (46.0) | |
| ACE-inhibitor/ARB | – | 61 (70.1) | |
| Verapamil/diltiazem | – | 6 (6.9) | |
| Mineralocorticoid receptor antagonist | – | 9 (10.3) | |
| Statins | – | 52 (59.8) | |
| Class I antiarrhythmic drug | – | 8 (9.2) | |
| Class III antiarrhythmic drug | – | 9 (10.3) | |
| Anticoagulant | – | 58 (66.7) | |

Bold values highlight statistical significance. ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; ARVC, arrhythmogenic right ventricular cardiomyopathy; CHD, congenital heart disease; DCM, non-ischaemic dilated cardiomyopathy; ICD/CRT-D, implantable cardioverter-defibrillator +/- -resynchronization therapy; ICM, ischaemic cardiomyopathy; HCM, hypertrophic cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; SCM, structural cardiomyopathy; TIA, transient ischaemic attack; VHD, valvular heart disease.
patterns of time-to-completion AER, which were significantly faster in the older population of patients with pacemakers compared with the ICD/CRT-D population. Individual patterns of AER progression could be estimated using the predicted values of AAR at the completion of the AER process and the computed slope at 25% of the expected change in AAR from the initiation to complete electrical remodelling in persistent AF.

The influence of the underlying cardiac condition and therapies (e.g. CRT-D) on AARs may represent different predominant mechanisms affecting atrial electrophysiology. Yoshida et al. have reported a direct relationship between LA pressure and the DF of AF at the LA appendage. Thus, atrial stretch in the presence of increased intracavitary pressures may lead to faster AARs as we have documented in patients with DCM. Slower AARs during paroxysmal AF episodes in patients with CRT-D compared with ICD patients may also reflect an improvement in cardiac haemodynamic status upon resynchronisation therapy. Interestingly, the majority of patients with other structural cardiomyopathies had hypertrophic cardiomyopathy, which is also associated with atrial diastolic dysfunction and increased LA pressures. Therefore, atrial stretch may represent the cause of faster AARs in patients with other structural cardiomyopathies compared with patients with ICM. Although patients with ICM can also have increased intracavitary pressures, infarct-related scar tissue may affect atrial activation and potentially decrease AAR. The latter would be consistent with the study by Swartz et al. showing aninverse correlation between LA fibrosis and LA activation frequencies. This is also consistent with our data from patients with pacemakers; a more advanced age in this population justifies higher levels of underlying atrial fibrosis and significantly slower AAR during paroxysmal AF, compared with the ICD/CRT-D population. At the cellular level, the myofibroblast/myocyte ratio in two-dimensional cardiac monolayers has also shown an inverse relationship with activation frequencies of re-entrant activity.

The data demonstrate the potential of personalized monitoring of AARs as a marker of electrical remodelling during AF progression. Moreover, regardless of the current classification of paroxysmal vs.

---

### Table 2 Baseline clinical and demographic characteristics of patients with implantable cardioverter-defibrillator+/−-resynchronization therapy devices in different atrial fibrillation groups

| Clinical characteristics | Paroxysmal AF (n = 427) | Complete AER progression (n = 200) | Persistent AF (n = 116) | P-value |
|--------------------------|--------------------------|-----------------------------------|------------------------|---------|
| Age (years), median [IQR] | 66.2 [58.1, 72.9]        | 67.9 [58.1, 74.5]                 | 69.3 [62.7, 75.3]      | 0.005   |
| Male, n (%)              | 334 (78.2)               | 178 (89.0)                        | 97 (83.6)              | 0.004   |
| Cardiomyopathy, n (%)    |                          |                                   |                        | 0.575   |
| ICM                      | 214 (50.1)               | 101 (50.5)                        | 61 (52.6)              |         |
| DCM                      | 141 (33.0)               | 68 (34.0)                         | 38 (32.8)              |         |
| Other SCM: HCM, ARVC, VHD, or CHD | 55 (12.9) | 29 (14.5)                        | 13 (11.2)              |         |
| Non-structural arrhythmogenic disease | 17 (4.0) | 2 (1.0)                          | 4 (3.4)                |         |
| LBBB, n (%)              | 195 (46.5)               | 84 (42.0)                         | 55 (48.7)              | 0.444   |
| LVEF (<35%), n (%)       | 303 (71.1)               | 147 (73.5)                        | 94 (81.7)              | 0.073   |
| Functional class, n (%)  |                          |                                   |                        | 0.073   |
| NYHA I                   | 79 (21.6)                | 30 (16.8)                         | 10 (9.1)               |         |
| NYHA II                  | 156 (42.7)               | 80 (44.7)                         | 52 (47.3)              |         |
| NYHA III                 | 124 (34.0)               | 67 (37.4)                         | 44 (40.0)              |         |
| NYHA IV                  | 6 (1.6)                  | 2 (1.1)                           | 4 (3.6)                |         |
| Clinical history, n (%)  |                          |                                   |                        | 0.891   |
| Hypertension             | 244 (59.2)               | 120 (61.2)                        | 70 (60.3)              |         |
| Diabetes mellitus        | 134 (32.5)               | 57 (28.5)                         | 36 (31.0)              | 0.601   |
| Hyperlipidaemia          | 220 (55.1)               | 110 (55.0)                        | 58 (51.8)              | 0.812   |
| Current smoking          | 127 (32.5)               | 53 (28.8)                         | 26 (24.5)              | 0.253   |
| Chronic renal failure    | 73 (18.0)                | 44 (22.6)                         | 26 (22.6)              | 0.312   |
| Previous stroke or TIA   | 24 (6.3)                 | 16 (8.7)                          | 10 (9.1)               | 0.464   |
| Clinical presentation, n (%) |                  |                                   |                        |         |
| Asymptomatic             | 184 (44.0)               | 92 (46.5)                         | 44 (39.3)              | 0.473   |
| Syncope                  | 68 (16.3)                | 32 (16.2)                         | 18 (16.1)              | 0.999   |
| Sudden cardiac death     | 40 (9.6)                 | 15 (7.6)                          | 7 (6.3)                | 0.459   |
| Primary prevention, n (%)| 305 (71.4)               | 143 (71.5)                        | 85 (73.3)              | 0.923   |
| Device type (ICD), n (%) | 229 (53.6)               | 91 (45.5)                         | 41 (35.3)              | <0.001  |

ACE, angiotensin-converting-enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; ARVC, arrhythmogenic right ventricular cardiomyopathy; CHD, congenital heart disease; DCM, non-ischaemic dilated cardiomyopathy; ICD/CRT-D, implantable cardioverter-defibrillator+/−-resynchronization therapy; ICM, ischaemic cardiomyopathy; HCM, hypertrophic cardiomyopathy; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; SCM, structural cardiomyopathy; TIA, transient ischaemic attack; VHD, valvular heart disease.
persistent AF, which does not provide accurate information about the underlying remodelling stage, our approach to assess the progression and stage of AER may have important therapeutic and prognostic implications. Lankveld et al. have documented that slower AARs on single surface ECG recordings of patients with persistent AF undergoing electrical cardioversion were associated with sinus rhythm maintenance after 1 year of follow-up. Interestingly, the mean episode duration was 3 months in patients with and without AF recurrences, which suggests that within the same time period slower progression of AER will lead to slower AARs and higher probability of sinus rhythm maintenance. Bollman et al. have also shown that single ECG-derived atrial fibrillatory frequencies of 5.9 Hz in patients with persistent AF were associated with successful pharmacological cardioversion. Conversely, mean atrial fibrillatory frequencies of 6.4 Hz did associate with unsuccessful pharmacological cardioversion, while mean episode duration (4 to 6 months) was not significantly
different between the two groups. Data from ablation procedures have also documented the role of ECG-based parameters to predict AF termination during the procedure and long-term freedom from AF. Using a retrospective cohort of patients undergoing persistent AF ablation, Lankveld et al.\(^\text{16}\) could document that DF values <6.0 Hz were frequently associated with AF termination during the ablation procedure, along with long-term freedom from the arrhythmia. Such DF values were mainly present in AF episodes with duration <12 months. The latter is consistent with our data in which the majority of patients in the ICD/CRT-D population (\(n = 150, \text{75th percentile}\)) showed complete electrical remodelling after 191 days of remodelling initiation.

Remote monitoring of different cardiac conditions has already demonstrated an impact on clinical outcomes, health care utilization
Continuous ECG monitoring with implantable cardiac monitors has also demonstrated that AF detection can be substantially improved in patients at high risk of both AF and stroke. However, despite the potential impact of early AF detection on clinical outcomes as rhythm control or stroke, data from trials with early therapeutic interventions are warranted. Our data represent one step forward in AF monitoring to detect both the electrical remodeling stage during AF episodes and the progression rate of AER as AF evolves. These two aspects may potentially assist physicians in personalized care of patients with AF and implantable devices; e.g.

### Table 3  
Univariate analysis of variables potentially associated with atrial activation rates during persistent atrial fibrillation after completion of atrial electrical remodelling

| Clinical characteristics                                                       | No         | Yes        | P-value/R²  |
|-------------------------------------------------------------------------------|------------|------------|-------------|
| Age                                                                           |            |            | 0.002/0.047|
| Male, n (Hz)                                                                  | 22 (6.29)  | 178 (6.40) | 0.925/-     |
| Cardiomyopathy, n (Hz)                                                        |            |            | 0.008/-     |
| ICM                                                                           | 101 (6.30) |            |             |
| DCM                                                                           | 68 (6.48)  |            |             |
| Other SCM: HCM, ARVC, VHD, or CHD                                            | 29 (6.93)  |            |             |
| Non-structural arrhythmogenic disease                                         | 2 (7.76)   |            |             |
| LBBB, n (Hz)                                                                  | 116 (6.40) | 84 (6.28)  | 0.536/-     |
| LVEF (≤35%), n (Hz)                                                           | 53 (6.84)  | 147 (6.30) | 0.013/-     |
| Functional class, n (Hz)                                                      |            |            | 0.194/-     |
| NYHA I                                                                        | 30 (6.60)  |            |             |
| NYHA II                                                                       | 80 (6.39)  |            |             |
| NYHA III                                                                      | 67 (6.30)  |            |             |
| NYHA IV                                                                       | 2 (5.26)   |            |             |
| Clinical history, n (Hz)                                                      |            |            |             |
| Hypertension                                                                  | 76 (6.31)  | 120 (6.39) | 0.930/-     |
| Diabetes mellitus                                                             | 143 (6.40) | 57 (6.30)  | 0.314/-     |
| Hyperlipidaemia                                                               | 90 (6.47)  | 110 (6.28) | 0.136/-     |
| Current smoking                                                               | 131 (6.28) | 53 (6.50)  | 0.169/-     |
| Chronic renal failure                                                         | 151 (6.30) | 44 (6.43)  | 0.671/-     |
| Previous stroke or TIA                                                        | 167 (6.30) | 16 (6.86)  | 0.242/-     |
| Clinical presentation, n (Hz)                                                 |            |            |             |
| Asymptomatic                                                                  | 106 (6.27) | 92 (6.42)  | 0.263/-     |
| Syncope                                                                       | 166 (6.40) | 32 (6.30)  | 0.900/-     |
| Sudden cardiac death                                                          | 183 (6.36) | 15 (6.50)  | 0.787/-     |
| Primary prevention, n (Hz)                                                    | 57 (6.32)  | 143 (6.40) | 0.926/-     |
| Device type (ICD), n (Hz)                                                     | 109 (6.30) | 91 (6.44)  | 0.118/-     |
| AAR during paroxysmal AF                                                       |            |            | <0.001/0.424|

Data are shown as the number of patients (n) and the median AAR during persistent AF after completion of AER (Hz).

AAR, atrial activation rate; ACE, angiotensin-converting-enzyme; AER, atrial electrical remodelling; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; ARVC, arrhythmogenic right ventricular cardiomyopathy; CHD, congenital heart disease; DCM, non-ischaemic dilated cardiomyopathy; ICD/CRT-D, implantable cardioverter-defibrillator

### Table 4  
Predictive model of atrial activation rates during persistent atrial fibrillation after completion of atrial electrical remodelling

|                          | Estimate | Standard error | t-statistic | P-value |
|--------------------------|----------|----------------|-------------|---------|
| Intercept                | 2.947    | 0.270          | 10.923      | <0.0001 |
| Cardiomyopathy           | 0.258    | 0.071          | 3.6311      | <0.0001 |
| AAR during paroxysmal AF | 0.675    | 0.056          | 12.150      | <0.0001 |
| R²                       | 0.460    |                |             |         |

AAR, atrial activation rate; AF, atrial fibrillation.
adjusting medical therapy and further monitoring its effects or proposing an early interventional ablation procedure before completion of AER.

We have obtained AARs from intracardiac bipolar tracings, which provided local activation rates from the right atrium. However, remodelling progression could also be monitored using single-lead ECG tracings after QRS-T subtraction as it has been performed in animal models of long-standing persistent AF. The latter opens new diagnostical options for monitoring AF progression using non-invasive long-term recording devices such as smart watches or wearable Holter ECG, which would require implementing appropriate algorithms for QRS-T subtraction and optimization of remote transmissions once AF is detected. Importantly, AF is an irregular rhythm with variations in local AAR within specific time windows. Therefore, a single ECG tracing or DF value may not represent an accurate measurement of AAR compared with repeating measurements for the same day. In patients with complete monitoring of AER in the ICD/CRT-D population, we have used a median of 64 [34, 122] AF tracings per patient, which minimized this potential limitation. Moreover, estimated slope calculations were performed using median DF values for repeating tracings from the same day. The latter could be further improved using algorithms that can store reliable DF values or average atrial activation cycle lengths using repeating samples from the same day. The DF values will have the advantage of providing a rapid measurement with no need for detecting individual activations, which may be challenging in the presence of fragmented electrograms or low amplitude signals. In fact, low fibrillatory wave amplitudes are commonly present in long-standing AF episodes. Conversely, DF values may be affected by harmonic peaks, which may require improved algorithms or additional revision by the physician using representative tracings that could be transmitted to a cloud-based data tool and avoid compromising devices’ battery longevity.

Limitations

The design of the study did not enable us to obtain remote-monitoring transmissions using specific criteria, which could have improved the estimation of AER slopes. This limitation was more relevant in pacemaker devices, in which remote transmissions were not available and AF tracings were only obtained from stored AF episodes. Representative cases are shown in Supplementary material online, Figure S5.

The study was focused on monitoring AER using a large number of tracings during a long follow-up. However, other remodelling changes as structural remodelling were not thoroughly evaluated because of study design limitations to obtain such data in ICD/CRT-D patients. Pharmacological history was not included in the official data sheet at the time of ICD/CRT-D implantation, which precluded us from obtaining more meaningful data about specific drug effects on both AAR and the progression of AER. Slower progression of AER in patients with ICD/CRT-D devices may be related to a high percentage of these patients taking upstream therapies (based on historical series with ICD/CRT-D devices) compared with pacemaker patients (Supplementary material online, Figure S2). However, this study shows that regardless of the underlying pharmacological effects on remodelling slopes, AER could be efficiently monitored and estimated using current technology. The methodology used in this study is not available in clinical practice and would require further implementation in implantable devices or remote-monitoring platforms to validate the impact in prospective series.

Conclusion

Atrial fibrillation progression shows patient-specific patterns of AER, which can be estimated using the computed individual slope of AAR changes and the underlying cardiac condition.

Supplementary material

Supplementary material is available at Europace online.

Acknowledgments

We thank the UMBRELLA study (NCT01561144 at clinicaltrials.gov) and the scientific co-operation platform for providing a valuable source of data to independent investigators in Spain. We thank Stuart Pocock for his statistical advice.

Conflict of interest: none declared.

Funding

The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MCNU), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015–0505). This study was supported by grants from the Fondo Europeo de Desarrollo Regional (CEB16/11/00458) and the Spanish MCNU (SAF2016-80324-R). The study was also partially supported by the Fundación Interhospitalaria para la Investigación Cardiovascular (FIC, Madrid, Spain) and the Heart Rhythm Association of the Spanish Society of Cardiology (D.F.-R., J.J.G.-F.). JJ. is supported by R01 Grant HL122352 from the National Heart Lung and Blood Institute, USA National Institutes of Health.

References

1. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313–20.
2. Weng LC, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B et al. Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation 2018;137:1027–38.
3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78.
4. Isa R, Villacastin J, Moreno J, Perez-Castellano N, Salinas J, Dobrado M et al. Differentiating between atrial flutter and atrial fibrillation using right atrial bipolar endocardial signals. Rev Esp Cardiol 2007;60:104–9.
5. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31.
6. Martins RP, Kaur K, Hwang E, Ramirez RJ, Willis BC, Filgueiras-Rama D et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation 2014;129:1472–82.
7. Takemoto Y, Ramirez RJ, Yokokawa M, Kaur K, Ponce-Balbuena D, Sinno MC et al. Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes. JACC Basic Trans Sci 2016;1:143–54.
8. Quintanilla JG, Alfonso-Almazán JM, Perez-Castellano N, Pandit SV, Jalife J, Perez-Villacastin J et al. Instantaneous amplitude and frequency modulations detect the footprint of rotational activity and reveal stable driver regions as targets for persistent atrial fibrillation ablation. Circ Res 2019;125:609–27.
9. Yoshida K, Ulfarsson M, Oral H, Crawford T, Good E, Jongnarangsin K et al. Left atrial pressure and dominant frequency of atrial fibrillation in humans. Heart Rhythm 2011;8:181–7.
10. Geske JB, Soraja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007;116:2702–8.
11. Kyhl K, Vejlstrup N, Lonborg J, Treiman M, Ahtarovski KA, Helqvist S et al. Predictors and prognostic value of left atrial remodelling after acute myocardial infarction. Open Heart 2015;2:e000223.
12. Swartz MF, Fink GW, Lutz C, Taffet SM, Berenfeld O, Vikstrom KL et al. Left versus right atrial difference in dominant frequency, K(+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm 2009;6:1415–22.
13. Zlochiver S, Munoz V, Vikstrom KL, Taffet SM, Berenfeld O, Jalife J. Electrotropic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. Biophys J 2008;95:4649–60.
14. Lankveld T, de Vos CB, Limantoro I, Zeemering S, Ahtarovski KA, Helqvist S et al. Monitoring of electrical remodelling during AF progression. Heart Rhythm 2015;12:2279–86.

A 62-year-old man with a history of mitral valve repair and cavo-tricuspid isthmus ablation underwent catheter ablation for persistent atrial flutter. The right atrial activation and voltage maps during the flutter demonstrated its re-entry circuit rotating around the superior vena cava (SVC) and a linear scar in the anteroseptal wall (Upper Panel). The scar contained a small area of preserved voltage near the tricuspid valve annulus (dashed arrows). The low-voltage fractionated potentials lasting 100 ms, suggest an area of slow conduction, and His potentials were simultaneously recorded in the grid mapping catheter (Lower Panel). Concealed entrainment was demonstrated by pacing from multiple sites around the SVC, leading to a diagnosis of upper loop re-entry (ULR). A single radiofrequency application at the slow conduction area, 15 mm superolateral to the site recording the His potential (white tags), successfully terminated the flutter.

Upper loop re-entry atrial flutter with its critical isthmus identified in the vicinity of his bundle

Tomoki Watanabe, Nobuhiro Takesushi,*, Genki Naruse, and Hiroyuki Okura
Division of Cardiovascular Medicine, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan
* Corresponding author. Tel: +81 58 230 6523; fax: +81 58 230 6524. E-mail address: sunanezumi417@yahoo.co.jp

The full-length version of this report can be viewed at https://www.escardio.org/Education/E-Learning/Clinical-cases/Electrophysiology.